Clinical Trials Logo

Clinical Trial Summary

The COPENHAGEN School Study is a combined cross-sectional and longitudinal study of healthy Danish school children. This study will by clinical examinations and withdrawal of blood samples investigate whether age of pubertal onset is continuing to decline in Denmark over the past 15 years. Furthermore, we will investigate the mechanism driving earlier onset of puberty and the long term health risks of extremely early puberty using Danish registry data


Clinical Trial Description

Cross-sectional School study: All children will be examined once and the following data will be collected: 1. Clinical medical examination of the child consisting of height measurements (standing- and sitting-height), arm-span, weight, fat fold measurements (biceps, triceps, flank, subscapularis), circumference of waist and hip, waist-hip ratio, blood pressure, body fat composition. Puberty development will be assessed by trained and experienced clinical personal according to Tanner criteria. Girls will be investigated for assessment of breast development stage B1-5 (by palpation), pubic hair staging PH1-5, occurrence of axillary hair (Stage 0-2), menarche (yes / no), sweat (yes/no) and acne (yes/no), and boys, their genitalia development stage G1-5, pubic hair stage PH1-6, occurrence of axillary hair (yes/no), acne (yes/no), sweat (yes/no), voice frequency, and voice break (yes/no). The testicular volume assessed by means of Praders orchidometer. 2. Blood sample (35 ml) for measurement of: a) Hormone levels, peptides and growth factors (FSH, LH, estradiol (total/free), progesterone, estrone/estrone sulphate, SHBG, testosterone (total/free), DHEAS, 17-hydroxyprogestrerone, androstenedione, 11-dinhibin B, AMH, INSL3 (only boys), kisspeptin, ghrelin, leptin, IGF-1, IGFBP-3, IGF-related peptides, eoxycortisol, cortisol, cortisone, RANKL, OPG, fibroblast growth factor 23 (FGF23), TSH, T4, free T4, T3, free T3, HbA1C, calcium ion, alkaline phosphatase, PTH, magnesium, phosphate, 25-OH-vitamin D, osteocalcin, prolactin, insulin and lipids (HDL, LDL, TG, Ip(a), cholesterol and lipoproteins), blood metabolites (e.g. amino acids, biogenic amines, acylcarnitines, lyso-phosphatidylcholines, phosphatidylcholines, sphingomyelins and hexose) and proteins (e.g. cytokines, growth factors, kinases, plasma receptors, proteases, protease inhibitors, plasma hormones and structural proteins)); b) Endocrine disrupters (PCBs, dioxins, parabens and phtalates); and c) DNA and RNA 3. Spot urine sample (100 ml) for measurement of FSH, LH, testosterone and endocrine disrupters ( parabens, pthalates, bisphenol A, UV-filters and triclosan) 4. Self-administered electronic questionnaire collecting information on previous growth, illness, living conditions, lifestyle factors, parents' puberty history and current hight and weight. Biobank Blood and urine samples will be temporary stored during the data collection period until 30th of July 2026. After this date, all unused serum, urine and DNA/RNA not used in the planned analyses will be stored at the established permanent (RegionH, Fælles Fryserfaciliteter) biobank (BIOSEK). The period of storage here is 30 years from the date that the temporary storage is closed. Prospective Registry-based Cohort study of the Long-term health and death risk after extremely early puberty: With a follow-up design, we will assess risk of morbidity and mortality amongst cases and referent children. Hazard rations (HRs) will be calculated using Cox regression analyses with stratification using each case and his/her matched referent subjects as a stratum. This ensures that comparisons are adjusted for age and calendar time. Co-variates includes maternal (BMI, smoking, socioeconomic status) during the index pregnancy, also birth weight, length and head circumference of participants. All will be identified in national registries for all persons. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04884620
Study type Observational
Source Rigshospitalet, Denmark
Contact Anders Juul, PhD, DMSc
Phone +45 35 45 13 77
Email anders.juul@regionh.dk
Status Recruiting
Phase
Start date January 1, 2023
Completion date December 31, 2056

See also
  Status Clinical Trial Phase
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Recruiting NCT04203381 - Skeletal Health and Bone Marrow Composition Among Youth N/A
Enrolling by invitation NCT05463120 - Minipuberty of Infancy and the Timing of Pubertal Development in Adolescence: a Follow-up of the Infant Feeding and Early Development (IFED) Cohort
Recruiting NCT04723862 - Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism? Early Phase 1
Suspended NCT02611128 - Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia
Completed NCT01517139 - Diet and Nutrition Pilot Study for Chinese Adolescents and Their Mothers
Not yet recruiting NCT06237387 - Association of Acne Vulgaris With Oral Hygiene and Gingivitis
Recruiting NCT00929006 - Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism Early Phase 1
Recruiting NCT03068910 - Hyperandrogenemia and Altered Day-night LH Pulse Patterns Early Phase 1
Completed NCT01411527 - The COPENHAGEN Puberty Study
Recruiting NCT02155933 - Assessment of Day-night Secretion of Progesterone and LH Across Puberty
Recruiting NCT04424576 - Ovarian Morphology in Girls
Recruiting NCT02583646 - Investigating the Impact of Obesity on Pubertal Development in Girls